FOR ADULT PATIENTS WITH OVERT
HEPATIC ENCEPHALOPATHY (HE)
Reduction IN RISK OF OVERT HE RECURRENCE1*
Reduction IN RISK OF HE-RELATED HOSPITALIZATIONS1*
XIFAXAN has been clinically proven to reduce the risk of overt HE recurrence and HE-related hospitalizations in adults.1*
*See Study Design above.
The XIFAXAN Instant Savings Card program may provide eligible, commercially insured patients savings on their monthly copays for XIFAXAN.
This downloadable guide helps answer many of the questions your patients may have if they have been prescribed XIFAXAN. It also details the HE Living Program (H.E.L.P.) text message support available to patients and their caregivers.
Hepatic encephalopathy (HE) is a common complication of cirrhosis.2,3 Up to 50% of patients with cirrhosis develop HE, with symptoms that range from minimal to severe.2,3
Practice resources are available to support you and your HE patients.
References: 1. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. 3. Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89(2):241-253.
You are now going to be transferred to the portal intended IBS-D for healthcare professionals.